TC-2216 is a drug developed by Targacept which acts as a partial agonist at neural nicotinic acetylcholine receptors and was researched for the treatment of anxiety and depression.[1] It was unsuccessful as a therapeutic but is still used in pharmacological research as an alpha4beta2-selective antagonist.[2]

References

  1. ^ Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F (June 2007). "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem. 2 (6): 746–67. doi:10.1002/cmdc.200600207. PMID 17295372. S2CID 34763474.
  2. ^ Lippiello PM, Beaver JS, Gatto GJ, James JW, Jordan KG, Traina VM, Xie J, Bencherif M (2008). "TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity". CNS Neuroscience & Therapeutics. 14 (4): 266–77. doi:10.1111/j.1755-5949.2008.00054.x. PMC 6494058. PMID 19040552.
Allikas: https://en.wikipedia.org/wiki/TC-2216
No tags for this post.